The present study contributes to our understanding of the relationship among the progression of tau pathology as measured by [18F]-flortaucipir PET; the progression of the regional cortical atrophy, which is considered a marker of nonspecific neurodegeneration and neuronal loss; and cognitive decline in AD. This evidence concerns the gene MAPT and Alzheimer disease.